Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418493 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT03418493 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 63 participants.
The verdict
NCT03418493, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). This is a three-part study. Participants will enroll in only one part. Parts A and B are for healthy participants and Part C is for participants with psoriasis. Participation could last between 16 and 57 weeks.
Interventions
- DRUG Placebo - IV
- DRUG LY3316531 - IV
- DRUG LY3316531 - SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2019-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03418493
The ClinicalTrials.gov registry entry for NCT03418493 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo - IV is the first listed.
NCT03418493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03418493 about?
NCT03418493 is a clinical study titled "A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis". The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). This is a...
What is the current status of trial NCT03418493?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2018-01-30. Estimated completion is 2019-07-29.
What interventions are being tested in trial NCT03418493?
The interventions under investigation include: Placebo - IV (DRUG), LY3316531 - IV (DRUG), LY3316531 - SC (DRUG).
Who is sponsoring clinical trial NCT03418493?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.